3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies

Toxicology in Vitro

Volumn 28, Issue 1, 2014, Pages 104-112

  Mueller, Daniel ^a   Krämer, Lisa ^a   Hoffmann, Esther ^a   Klein, Sebastian ^a   Noor, Fozia ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Chronic toxicity; HepaRG; In vitro models; Organotypic cultures; Repeated dose toxicity

Indexed keywords

AFLATOXIN B1; AMIODARONE; CHLORPROMAZINE; CYTOCHROME P450 3A4; GLUCOSE; LACTIC ACID; VALPROIC ACID;

ARTICLE; CELL CULTURE; CELL FUNCTION; CELL STRAIN HEPARG; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; LIVER; SENSITIVITY ANALYSIS; THREE DIMENSIONAL ORGANOTYPIC CULTURE; TOXICITY TESTING;

ANIMALIA;

CHRONIC TOXICITY; HEPARG; IN VITRO MODELS; ORGANOTYPIC CULTURES; REPEATED DOSE TOXICITY;

ANIMAL TESTING ALTERNATIVES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DRUG-INDUCED LIVER INJURY; HEP G2 CELLS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TOXICITY TESTS; TOXICITY TESTS, ACUTE;

EID: 84888290491     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.06.024     Document Type: Article

References (66)

1. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34:75-83.
2. Antherieu S., Azzi P.B., Dumont J., Abdel-Razzak Z., Guguen-Guillouzo C., Fromenty B., Robin M.A., Guillouzo A. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Hepatology 2012.
3. Argikar U.A., Remmel R.P. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos. 2009, 37:229-236.
4. Baillie T.A. Metabolism of valproate to hepatotoxic intermediates. Pharm. Weekblad Sci. 1992, 14:122-125.
5. Bedard L.L., Massey T.E. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett. 2006, 241:174-183.
6. Biagini C.P., Boissel E., Borde F., Bender V.E., Bouskila M., Blazy F., Nicaise L., Mignot A., Cassio D., Chevalier S. Investigation of the hepatotoxicity profile of chemical entities using liverbeads and WIF-B9 in vitro models. Toxicol. In Vitro 2006, 20:1051-1059.
7. Broeders J.J., Blaauboer B.J., Hermens J.L. In vitro biokinetics of chlorpromazine and the influence of different dose metrics on effect concentrations for cytotoxicity in Balb/c 3T3, Caco-2 and HepaRG cell cultures. Toxicol. In Vitro 2013, 27:1057-1064.
8. Chaumontet C., Mazzoleni G., Decaens C., Bex V., Cassio D., Martel P. The polarized hepatic human/rat hybrid WIF 12-1 and WIF-B cells communicate efficiently in vitro via connexin 32-constituted gap junctions. Hepatology 1998, 28:164-172.
9. Corcuera L.A., Vettorazzi A., Arbillaga L., Gonzalez-Penas E., Lopez de Cerain A. An approach to the toxicity and toxicokinetics of aflatoxin B1 and ochratoxin A after simultaneous oral administration to fasted F344 rats. Food Chem. Toxicol. 2012.
10. Darnell M., Schreiter T., Zeilinger K., Urbaniak T., Soderdahl T., Rossberg I., Dillner B., Berg A.L., Gerlach J.C., Andersson T.B. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab. Dispos. 2011, 39:1131-1138.
11. Darnell M.H., Ulvestad M., Ellis E., Weidolf L., Andersson T.B. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and in a dynamic three-dimensional bioreactor system. J. Pharm. Exp. Ther. 2012.
12. Drewitz M., Helbling M., Fried N., Bieri M., Moritz W., Lichtenberg J., Kelm J.M. Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol. J. 2011, 6:1488-1496.
13. Eadie M.J., Hooper W.D., Dickinson R.G. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med. Toxicol. Adverse Drug Exp. 1988, 3:85-106.
14. Fey S.J., Wrzesinski K. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicol. Sci. 2012, 127:403-411.
15. Gerlach J.C., Mutig K., Sauer I.M., Schrade P., Efimova E., Mieder T., Naumann G., Grunwald A., Pless G., Mas A., Bachmann S., Neuhaus P., Zeilinger K. Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation 2003, 76:781-786.
16. Godoy P., Hengstler J.G., Ilkavets I., Meyer C., Bachmann A., Muller A., Tuschl G., Mueller S.O., Dooley S. Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology 2009, 49:2031-2043.
17. Golli-Bennour E.E., Bouslimi A., Zouaoui O., Nouira S., Achour A., Bacha H. Cytotoxicity effects of amiodarone on cultured cells. Exp. Toxicol. Pathol. 2012, 64:425-430.
18. Gomez-Lechon M.J., Donato M.T., Castell J.V., Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 2003, 4:292-312.
19. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA 2002, 99:15655-15660.
20. Guengerich F.P. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharm. 2011, 26:3-14.
21. Guillouzo A. Liver cell models in in vitro toxicology. Environ. Health Perspect. 1998, 106(Suppl. 2):511-532.
22. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 2007, 168:66-73.
23. Gunness P., Mueller D., Shevchenko V., Heinzle E., Ingelman-Sundberg M., Noor F. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci. 2013.
24. Haouzi D., Baghdiguian S., Granier G., Travo P., Mangeat P., Hibner U. Three-dimensional polarization sensitizes hepatocytes to Fas/CD95 apoptotic signalling. J. Cell Sci. 2005, 118:2763-2773.
25. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607-4612.
26. Hoekstra R., Nibourg G.A., van der Hoeven T.V., Ackermans M.T., Hakvoort T.B., van Gulik T.M., Lamers W.H., Elferink R.P., Chamuleau R.A. The HepaRG cell line is suitable for bioartificial liver application. Int. J. Biochem. Cell Biol. 2011, 43:1483-1489.
27. Horning J.L., Sahoo S.K., Vijayaraghavalu S., Dimitrijevic S., Vasir J.K., Jain T.K., Panda A.K., Labhasetwar V. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol. Pharm. 2008, 5:849-862.
28. Kanebratt K.P., Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 2008, 36:1444-1452.
29. Kashima A., Funahashi M., Fukumoto K., Komamura K., Kamakura S., Kitakaze M., Ueno K. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biol. Pharm. Bull. 2005, 28:1934-1938.
30. Kelm J.M., Fussenegger M. Microscale tissue engineering using gravity-enforced cell assembly. Trends Biotechnol. 2004, 22:195-202.
31. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol. Bioeng. 2003, 83:173-180.
32. Klein S., Heinzle E. Isotope labeling experiments in metabolomics and fluxomics. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 4:261-272.
33. Kono Y., Roberts E.A. Modulation of the expression of liver-specific functions in novel human hepatocyte lines cultured in a collagen gel sandwich configuration. Biochem. Biophys. Res. Commun. 1996, 220:628-632.
34. Kramer N.I., Krismartina M., Rico-Rico A., Blaauboer B.J., Hermens J.L. Quantifying processes determining the free concentration of phenanthrene in Basal cytotoxicity assays. Chem. Res. Toxicol. 2012, 25:436-445.
35. Larrey D., Pageaux G.P. Genetic predisposition to drug-induced hepatotoxicity. J. Hepatol. 1997, 26(Suppl. 2):12-21.
36. Latini R., Tognoni G., Kates R.E. Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet. 1984, 9:136-156.
37. Le Vee M., Jigorel E., Glaise D., Gripon P., Guguen-Guillouzo C., Fardel O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci. 2006, 28:109-117.
38. Leite S.B., Wilk-Zasadna I., Zaldivar Comenges J.M., Airola E., Reis-Fernandes M.A., Mennecozzi M., Guguen-Guillouzo C., Chesne C., Gouillou C., Alves P.M., Coecke S. 3D HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 2012.
39. Li A.P., Uzgare A., Laforge Y.S. Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen. Chem. Biol. Interact. 2012, 199:1-8.
40. Limonciel A., Aschauer L., Wilmes A., Prajczer S., Leonard M.O., Pfaller W., Jennings P. Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol. In Vitro 2011, 25:1855-1862.
41. Lubberstedt M., Muller-Vieira U., Mayer M., Biemel K.M., Knospel F., Knobeloch D., Nussler A.K., Gerlach J.C., Zeilinger K. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 2011, 63:59-68.
42. Mandenius C.F., Andersson T.B., Alves P.M., Batzl-Hartmann C., Bjorquist P., Carrondo M.J., Chesne C., Coecke S., Edsbagge J., Fredriksson J.M., Gerlach J.C., Heinzle E., Ingelman-Sundberg M., Johansson I., Kuppers-Munther B., Muller-Vieira U., Noor F., Zeilinger K. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. Altern. Lab. Anim. 2011, 39:147-171.
43. Mandenius C.F., Steel D., Noor F., Meyer T., Heinzle E., Asp J., Arain S., Kraushaar U., Bremer S., Class R., Sartipy P. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J. Appl. Toxicol. 2011, 31:191-205.
44. McGill M.R., Yan H.M., Ramachandran A., Murray G.J., Rollins D.E., Jaeschke H. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 2011, 53:974-982.
45. McLean M., Dutton M.F. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther. 1995, 65:163-192.
46. Mueller D., Koetemann A., Noor F. Organotypic cultures of HepG2 cells for in vitro toxicity studies. J. Bioeng. Biomed. Sci. S 2011, 2:002.
47. Mueller D., Tascher G., Muller-Vieira U., Knobeloch D., Nuessler A.K., Zeilinger K., Heinzle E., Noor F. In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J. Tissue Eng. Regen. Med. 2011, 5:e207-218.
48. Mueller D., Tascher G., Damm G., Nussler A.K., Heinzle E., Noor F. Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay. Cytotechnology 2012.
49. Narayanan R.A., Rink A., Beattie C.W., Hu W.S. Differential gene expression analysis during porcine hepatocyte spheroid formation. Mamm. Genome 2002, 13:515-523.
50. Nibourg G.A., Boer J.D., van der Hoeven T.V., Ackermans M.T., van Gulik T.M., Chamuleau R.A., Hoekstra R. Perfusion flow rate substantially contributes to the performance of the HepaRG-AMC-bioartificial liver. Biotechnol. Bioeng. 2012.
51. Nibourg G.A., Chamuleau R.A., van der Hoeven T.V., Maas M.A., Ruiter A.F., Lamers W.H., Oude Elferink R.P., van Gulik T.M., Hoekstra R. Liver progenitor cell line HepaRG Differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. PLoS One 2012, 7:e38778.
52. Niklas J., Noor F., Heinzle E. Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. Toxicol. Appl. Pharmacol. 2009, 240:327-336.
53. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos. 2000, 28:1303-1310.
54. Padda M.S., Sanchez M., Akhtar A.J., Boyer J.L. Drug-induced cholestasis. Hepatology 2012, 53:1377-1387.
55. Park B.K., Pirmohamed M., Kitteringham N.R. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther. 1995, 68:385-424.
56. Powell-Jackson P.R., Tredger J.M., Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984, 25:673-681.
57. Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B. The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Arch. Physiol. Biochem. 2012, 118:102-111.
58. Sauer I.M., Kardassis D., Zeillinger K., Pascher A., Gruenwald A., Pless G., Irgang M., Kraemer M., Puhl G., Frank J., Muller A.R., Steinmuller T., Denner J., Neuhaus P., Gerlach J.C. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation 2003, 10:460-469.
59. Schuster D., Laggner C., Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11:3545-3559.
60. Spaniol M., Bracher R., Ha H.R., Follath F., Krahenbuhl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 2001, 35:628-636.
61. van de Kerkhove M.P., Di Florio E., Scuderi V., Mancini A., Belli A., Bracco A., Scala D., Scala S., Zeuli L., Di Nicuolo G., Amoroso P., Calise F., Chamuleau R.A. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplant. 2003, 12:563-568.
62. Waldhauser K.M., Torok M., Ha H.R., Thomet U., Konrad D., Brecht K., Follath F., Krahenbuhl S. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 2006, 319:1413-1423.
63. Waldhauser K.M., Brecht K., Hebeisen S., Ha H.R., Konrad D., Bur D., Krahenbuhl S. Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Brit. J. Pharmacol. 2008, 155:585-595.
64. Wen B., Zhou M. Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chem. Biol. Interact. 2009, 181:220-226.
65. Winter H.R., DeVane C.L., Figueroa C., Ennis D.J., Hamer-Maansson J.E., Davis P.C., Smith M.A. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum. Psychopharmacol. 2007, 22:469-476.
66. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.